10-K: Bakhu Holdings Corp. Files Annual Report Amidst Financial Struggles

Bakhu Holdings Corp. files its Form 10-K for the fiscal year ended July 31, 2024, detailing significant financial challenges, ongoing efforts to secure funding, and operational suspensions.

Summary

• Bakhu Holdings Corp. has filed its annual report on Form 10-K for the fiscal year ended July 31, 2024.
• The company's operations were severely impacted by a lack of working capital and cash throughout the year.
• Bakhu Holdings has not generated any revenue and has accumulated a significant deficit.
• The company is in default on a $150,000 promissory note to OZ Company and faces substantial liabilities to related parties.
• All officers and directors resigned in January 2025, leading to a suspension of operations.
• Recent appointments of new management and directors in March and April 2026 indicate efforts to restore the company's standing.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's lack of revenue, operational suspension, significant debt, auditor's going concern warning, and identified material weaknesses in internal controls.

Positives

• The company has secured new management and directors in March and April 2026, signaling a potential path forward.
• Recent financing efforts, though limited, have provided some cash to address operational needs.
• The company has entered into agreements for potential future funding and restructuring.

Negatives

• The company has no revenue and a significant accumulated deficit of $50,911,157 as of July 31, 2024.
• Operations were suspended in January 2025 due to the resignation of all officers and directors.
• The company is in default on a $150,000 promissory note to OZ Company.
• Substantial liabilities to related parties, including notes payable to Cell Science and OZ Company, total over $7.6 million.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting have been identified.
• The company's common stock is quoted on the Expert Market, with no published quotation and restricted public viewing, significantly impacting liquidity and trading risks.

Risks

• The company's entire business relies on the commercial-scale validation of its licensed cell-extraction and replication technology, which has not been fully achieved.
• The company faces significant regulatory hurdles and uncertainties related to the cannabis industry at both federal and state levels.
• Failure to secure substantial additional financing could lead to the abandonment of its technology commercialization efforts and suspension of operations.
• The company's licensed technology has only been tested on a limited basis by related parties without qualified third-party replication, raising concerns about its credibility.
• The company is in default on a promissory note and has substantial past-due liabilities, including to related parties.
• The company's auditor has identified material weaknesses in internal controls, increasing the risk of financial misstatements.
• The company's common stock is illiquid and traded on the Expert Market, posing significant risks to investors.
• There are ongoing legal disputes and claims related to the company's license and intellectual property.

Future Outlook

The company requires substantial additional financing to fund its planned laboratory activities, commercialization efforts, and meet financial obligations. Without this financing, the company may have to abandon its current business plan and seek other opportunities or suspend operations. Recent management changes and potential funding agreements offer a path to restore regulatory compliance and operations.

Management Comments

• Our funding efforts during the fiscal year ended July 31, 2024 were unsuccessful and our financing efforts continued to be unsuccessful thereafter.
• We have identified material weaknesses in our internal control over financial reporting that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements.
• Our auditor stated in its report on our July 31, 2024, audited financial statements that it has substantial doubt that we will be able to continue as a going concern without further financing.

Industry Context

StockSavvy.ai notes that Bakhu Holdings operates in the highly regulated and evolving cannabis industry, facing challenges common to early-stage companies in this sector, including significant capital requirements, complex regulatory landscapes, and the need for technological validation. The company's reliance on a novel plant cell-extraction and replication technology places it at the forefront of potential innovation but also introduces unique regulatory and market acceptance risks.

Management Changes

Corporate Governance

Legal Proceedings

• A minority stockholder of Mentone Ltd. has claimed unlawful removal from the board and unauthorized agreements related to the licensed technology, threatening litigation.
• A purported complaint was filed in Cyprus by the Mentone minority stockholder against Bakhu Holdings, one prior director, and one former director/officer.
• Cell Science Holding Ltd. and Inter-M Traders FZ LLE have issued a Formal Notice of Breach, Misrepresentation, Demand for Preservation of Evidence, and Reservation of Rights against Bakhu and Peter Whitton, alleging failures in technology development and validation.

Related Party Transactions

• Office Cost Sharing Agreement with OZ Company for $34,000 per month, with $1,409,000 owed as of July 31, 2024.
• Significant notes payable to related parties, including Cell Science ($3,170,000) and OZ Company ($3,780,872 for a working capital note and $150,000 for another note, plus a convertible senior secured note).
• The company's license for its core technology was obtained from Cell Science, which has ownership ties to Inter-M Traders FZ LLE and OZ Company.
• Previous directors and officers had substantial conflicts of interest due to affiliations with Cell Science and its affiliates.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity issuances and the illiquid nature of the Expert Market trading.
• Creditors, including related parties, face uncertainty regarding the repayment of substantial outstanding liabilities.
• Potential commercialization partners may be hesitant to engage due to the company's financial instability, operational suspension, and unproven technology at scale.
• Employees have been impacted by the suspension of operations and the general uncertainty surrounding the company's future.

Next Steps

• Secure substantial additional financing to fund laboratory activities, commercialization efforts, and meet financial obligations.
• Recruit and retain executive officers and directors to organize the relaunch of commercialization efforts.
• Initiate conversations with potential commercialization partners, particularly multi-state operators.
• Address and rectify material weaknesses in internal control over financial reporting.
• Bring delinquent SEC filings current to restore regulatory good standing.

Key Dates

Recommendation

The company exhibits severe financial distress, operational cessation, and significant going concern risks. The lack of revenue, substantial debt, auditor's concerns, and identified control weaknesses, coupled with the illiquid trading status of its stock, make it an extremely high-risk investment. While new management has been appointed, the path to recovery is highly uncertain and requires substantial capital infusion and successful operational and regulatory navigation.

Keywords

Bakhu Holdings, Form 10-K, Cannabinoid Technology, SEC Filing, Financial Report, Going Concern, Licensing Agreement, Cannabis Industry